Related Experiment Videos
[Preclinical pharmacologic evaluation of bleomycin A6]
1Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, Beijing.
Summary
Bleomycin A6, an antineoplastic antibiotic, showed dose-dependent toxicity, primarily affecting kidneys in rats and dogs at higher doses. Lower doses were well-tolerated in dogs, with no significant local changes observed in rabbits.
Area of Science:
- Pharmacology
- Toxicology
- Oncology
Background:
- Bleomycin A6 is an antineoplastic antibiotic used in cancer treatment.
- Understanding its toxicological profile is crucial for safe clinical application.
Purpose of the Study:
- To evaluate the toxicological effects of Bleomycin A6 in various animal models.
- To determine dose-limiting toxicities and target organs.
Main Methods:
- Acute toxicity (LD50) was determined in mice via multiple routes of administration.
- Subchronic toxicity was assessed in Wistar rats and dogs following intraperitoneal and intravenous administration, respectively.
- Local tolerance was evaluated in rabbits after intramuscular and intravenous injections.
Main Results:
- LD50 values varied by administration route in mice.
- Rats receiving >2 mg/kg/day Bleomycin A6 intraperitoneally for 60 days exhibited renal damage.
- Dogs treated with 1.0 mg/kg intravenously daily showed mortality, renal damage, and skin ulceration; 0.1 mg/kg was well-tolerated.
Conclusions:
- Bleomycin A6 exhibits dose-dependent toxicity, with the kidney as a primary target organ.
- Careful dose selection and monitoring are essential for minimizing Bleomycin A6-induced toxicity in clinical settings.